Novaremed Secures Additional Financing and Strengthens Leadership
2.9.2019 12:38:00 EEST | Business Wire | Press release
Novaremed AG (Novaremed), a clinical-stage Swiss biopharmaceutical company, today announced that it has secured CHF2.6 million in additional financing from its existing shareholders and several new private investors. This brings the total financing raised by the company, since its inception, to CHF21 million. In addition, the company announced that Subhasis Roy, Novaremed’s COO since April 2018, will be stepping up and fulfilling the role of Interim CEO.
The recent funding and strengthened leadership team are both integral developments for Novaremed as the company accelerates its preparation towards initiating a Phase 2b study in Diabetic Neuropathic Pain (DNP). The company is pleased to have received positive feedback from the FDA from their recently conducted Pre-IND meeting, which sets the path forward for the IND opening of the Phase 2b study in DNP.
"This additional financing underscores the commitment of our shareholders and private investors, as well as their faith in Novaremed’s potential," said Harry Welten, Chairman of the Board of Novaremed. "Novaremed is well-positioned with a seasoned leadership team, led by Subhasis, to drive Novaremed’s clinical development and operations forward."
Notes to the Editor:
About Novaremed
Novaremed Ltd. was founded in 2008 in Israel and transferred its corporate headquarters to Novaremed AG, founded in November 2017 in Switzerland. Novaremed is developing NRD.E1, an orally active non-opioid small molecule with a new mechanism of action for the treatment of DNP. In a Phase 2a Proof of Concept study, NRD.E1 showed clinically relevant reduction in patient reported pain. Novaremed is currently preparing for a global Phase 2b study in DNP, expected to start in Q2/3 2020. For more information, visit www.novaremed.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190902005074/en/
Contact information
Subhasis Roy, Interim CEO/COO
Tel: +41 79 2075715
Email:
subhasis.roy@novaremed.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 202629.7.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that it will release financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on August 5, 2026. A live webcast of the call will be available on the Compass Pathways website at: https://events.q4inc.com/attendee/246696001. The webcast will be archived for 30 days. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation for treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD
Opzelura ® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis29.7.2026 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. "The European Commission's approval of Opzelura is an important milestone for adults in Europe living with moderate atopic dermatitis who need more treatment options," said Bill Meury, Chief Executive Officer, Incyte. "As the first steroid-free topical JAK inhibitor approved in the EU for atopic dermatitis, Opzelura offers an effective new treatment choice and reflects our commitment to advancing innovation for people with inflammatory and autoimmune diseases." The EC decision follows the June 2026 positive opinion received from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This marks the second indication in Europe for Opzelura, which was previously
NTT DATA and ENGIE Announce Strategic Partnership to Power Sustainable AI and Data Center Growth29.7.2026 12:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, and ENGIE, a major player in the energy transition, today announced a strategic partnership to support the decarbonization, energy resilience and sustainable expansion of NTT DATA’s global data center operations. By combining ENGIE’s global leadership in renewable energy and low‑carbon solutions with NTT DATA’s infrastructure and technology services, the partnership secures long-term access to competitive renewable energy and power solutions that support the continued growth of NTT DATA’s data centers and AI infrastructure while addressing its net-zero ambitions. The partnership reflects NTT DATA's commitment to securing the long-term energy solutions required to support the next generation of AI, cloud and digital infrastructure growth. The objective is to move beyond a traditional supplier relationship, establishing a long-term framework covering renewable energy procurement, power supply and integrated energy
Quectel Launches High-Performance FCM665D Module for Edge AI Applications29.7.2026 12:00:00 EEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM665D, a high-performance Wi-Fi 6 and Bluetooth module with edge AI processing capabilities, designed for smart home, smart building and industrial IoT devices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729751874/en/ Quectel launches high-performance FCM665D module for edge AI applications Designed for products such as smart lighting, video doorbells and central control hubs, the FCM665D pairs high-performance connectivity with on-device intelligence, giving manufacturers a way to build faster, smarter, more capable devices without leaning on constant cloud connectivity. “This module has the AI capabilities and processing power to compete at the highest level,” said Delbert Sun, Vice General Manager, Product Department, Quectel Wireless Solutions. “Smart home and IoT devices are required to do more locally at t
1NCE and Pessl Instruments Connect Smart Farms Worldwide29.7.2026 11:00:00 EEST | Press release
1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, and Pessl Instruments, a global leader in smart agriculture, announce today the roll-out of the METOS by Pessl Instruments weather network solution powered by 1NCE. The smart farming solution provided by Pessl Instruments connects thousands of weather stations and field sensors through a single platform, providing farmers real-time data of precipitation and soil moisture, extreme weather forecasting and crop disease risk in more than 80 countries. The main challenge for the deployment of smart farming solutions is always providing good coverage in rural areas. Thanks to 1NCE’s global connectivity service available in more than 170 countries, Pessl Instruments can now offer its smart farming solution at global scale with a 99.97% service availability. This consolidates Pessl Instruments as a smart farming powerhouse, helping customers make more informed irrigation and fertilizer de
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom